Literature DB >> 7036730

Neurogenic disorders of osmoregulation.

G L Robertson, P Aycinena, R L Zerbe.   

Abstract

The osmolality of body fluids is normally maintained within a narrow range. This constancy is achieved largely via hypothalamic osmo-receptors that regulate thirst and arginine vasopressin, the antidiuretic hormone (ADH). Anything that interferes with the full expression of either osmoregulatory function exposes the patient to the hazards of abnormal increases or decreases in plasma osmolality. Hyposmolality is almost always due to a defect in water excretion. Increased intake may contribute to the problem but is rarely, if ever, a sufficient cause. Impaired water excretion can be due to a primary defect in the osmoregulation of ADH (inappropriate antidiuresis) or secondary to nonosmotic stimuli like hypovolemia or nausea. The two types differ in clinical presentation and treatment. Resetting of the ADH osmostat is commonly associated with resetting of the thirst osmostat. Hyperosmolarity is almost always due to deficient water intake. Excessive excretion may contribute to the problem but is never a sufficient cause. Impaired water intake can result from a defect in either the osmoregulation of thirst of the necessary motor responses. Thirst may be deficient because of primary osmoreceptor damage as in the syndrome of adipsic hypernatremia or secondary to nonosmotic influences on the set of the system. They are distinguishable by the clinical presentation as well as the type of ADH defects with which they are associated. So-called essential hypernatremia due to primary resetting of the osmostat has been postulated, but unambiguous evidence for such an entity has not yet been reported.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7036730     DOI: 10.1016/0002-9343(82)90825-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  35 in total

1.  Management of adipsia by a behavioural modification technique.

Authors:  S Johnston; J Burgess; T McMillan; R Greenwood
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

2.  American Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders.

Authors:  Mitchell H Rosner; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-29       Impact factor: 8.237

3.  "Thirst strike": hypernatraemia and acute prerenal failure in a prisoner who refused to drink.

Authors:  M Neeser; P Ruedin; J P Restellini
Journal:  BMJ       Date:  1992-05-23

4.  Beyond semantics: defining hyponatremia in secondary adrenal insufficiency.

Authors:  M Faustini-Fustini; M Anagni
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 5.  Vaptans for the treatment of hyponatremia.

Authors:  Gary L Robertson
Journal:  Nat Rev Endocrinol       Date:  2011-02-01       Impact factor: 43.330

6.  Syndrome of inappropriate antidiuretic hormone secretion in a dog.

Authors:  D M Houston; D G Allen; S A Kruth; H Pook; M T Spinato; L Keough
Journal:  Can Vet J       Date:  1989-05       Impact factor: 1.008

7.  Effects of athletes' muscle mass on urinary markers of hydration status.

Authors:  Nassim Hamouti; Juan Del Coso; Andrea Avila; Ricardo Mora-Rodriguez
Journal:  Eur J Appl Physiol       Date:  2010-01-08       Impact factor: 3.078

8.  Adipsic hypothalamic diabetes insipidus after clipping of anterior communicating artery aneurysm.

Authors:  B McIver; A Connacher; I Whittle; P Baylis; C Thompson
Journal:  BMJ       Date:  1991-12-07

9.  Potential impact of a 500-mL water bolus and body mass on plasma osmolality dilution.

Authors:  Kurt J Sollanek; Robert W Kenefick; Samuel N Cheuvront; Robert S Axtell
Journal:  Eur J Appl Physiol       Date:  2011-01-20       Impact factor: 3.078

10.  Adipsic hypernatremia in a patient with pseudotumor cerebri and the primary empty sella syndrome.

Authors:  E Verdin; S Smitz; A Thibaut; J Born; J J Legros; A Luyckx
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.